Drug Trial Radar · NCT04234607
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
738
Planned (sponsor's estimate)
Start
Jan 2020
Primary completion
Dec 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, controlled, multicenter phase III study of TQB2450 or placebo combined with Anlotinib, etoposide and carboplatin versus Etoposide and Carboplatin in subjects with extensive small cell lung cancer. The primary outcome measures include PFS and OS. Extended stage Small Cell Lung Cancer (SCLC) patients will be registered, after signing the informed consent, and then centrally randomized 1:1:1 to the experimental arms and the control arm.
Conditions
- Extensive Small Cell Lung Cancer
Interventions
TQB2450Drug
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
AnlotinibDrug
a multi-target receptor tyrosine kinase inhibitor
EtoposideDrug
Etoposide is a cell cycle-specific antitumor drug
CarboplatinDrug
Carboplatin is cell cycle nonspecific antitumor drug
TQB2450(blank)Drug
Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Anlotinib(blank)Drug
Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: up to 12 months
- Overall survival (OS)Time frame: up to 24 months
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Anhui chest hospital
Hefei, Anhui, China
AnHui Provincial Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing chest hospital,capital medical university
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The Fiest Affiliated Hospital of Guanghzou University of Chinese Medicine
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China
Guizhou Provincial people's Hospital
Guiyang, Guizhou, China
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China
Shijiazhuang First Hospital
Shijiazhuang, Hebei, China
Hebei Chest Hospital
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Jinzhou Central Hospital
Jinzhou, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.